Degradation of toxins in vivo
AssigneeAperiam Bio, Inc.
InventorsAustin Woodrow Cole, Guillaume Cottarel
Life of this patent
Estimating the term…
Abstract
The present disclosure generally relates to technologies for the degradation a systemic toxin in vivo by enhancing the metabolic functionality of the lungs. Such technologies comprise introducing, to pulmonary tissue of a subject, a composition comprising at least one enzyme known to enzymatically break down at least one toxin present systemically in the subject. The provided technologies enable the lung to behave as a tunable metabolic organ, facilitating the removal of toxins from the systemic circulation of a subject, such as a subject having a condition resulting in the toxic accumulation or an endogenous metabolite, and a subject who has consumed a toxic substance.
Claims25
A method of alleviating one or more negative effects of a toxin in vivo comprising:
- (a) introducing at least one preselected enzyme to pulmonary tissue of a subject, said at least one preselected enzyme being known to enzymatically breakdown at least one toxin that is exerting one or more negative effects against said subject;
- and
- (b) allowing the enzymatic breakdown of said at least one toxin to take place in vivo, alleviating said one or more negative effects.
13-16. (canceled)
A method of transforming a lung of a subject to include at least one enzymatic breakdown function comprising introducing to a lung of a subject at least one preselected enzyme known to facilitate an enzymatic breakdown of at least one toxin that, if present, is present systemically in the subject.
18-21. (canceled)
A transformed pulmonary cell comprising an alveolar cell harboring at least one preselected enzyme known to enzymatically breakdown at least one toxin via an introduction of either a polypeptide having an amino acid sequence corresponding to said preselected enzyme, a polynucleotide encoding said polypeptide, or both.
23-25. (canceled)
A method of alleviating one or more negative effects of a condition in a subject, comprising:
- (a) introducing asparaginase to pulmonary tissue of a subject diagnosed with leukemia, and
- allowing asparaginase to enzymatically break down asparagine in vivo, thereby alleviating said one or more negative effects;
- or
- (b) introducing oxalate decarboxylase to pulmonary tissue of a subject diagnosed with oxalosis, primary hyperoxaluria, or secondary hyperoxaluria, and
- allowing the oxalate decarboxylase to enzymatically break down oxalate;
- or
- (c) introducing phenylalanine ammonia lyase (PAL) to pulmonary tissue of a subject with phenylketonuria, and
- allowing the PAL to enzymatically break down phenylalanine;
- or
- (d) introducing uricase to said pulmonary tissue of a subject with hyperuricemia, and
- allowing the uricase to enzymatically break down uric acid;
- or
- (e) introducing thiosulfate sulfurtransferase said pulmonary tissue of a subject with cyanide poisoning, and
- allowing the thiosulfate sulfurtransferase to enzymatically break down of said cyanide;
- or
- (f) introducing glutamine synthase to pulmonary tissue of a subject with hyperammonemia, and
- allowing the glutamine synthase to enzymatically break down ammonia;
- or
- (g) introducing arginase to pulmonary tissue of a subject with hyperargininemia;
- and
- allowing the arginase to enzymatically break down arginine.
27-39. (canceled)
42-43. (canceled)
46-54. (canceled)
Dependencies are inferred from the claim text.